MedTrace Logo

NovoLet® Surveillance Study on Using Human Insulin System in Indonesia

NCT01492153 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1981

Last updated 2017-02-28

No results posted yet for this study

Summary

This study is conducted in Asia. The aim of this study is to investigate the safety and efficacy of NovoLet® human insulin delivery system in an outpatient setting.

Conditions

  • Diabetes
  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2

Interventions

DRUG

biphasic human insulin

NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator

DRUG

isophane human insulin

NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator

DRUG

human soluble insulin

NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1457) · Novo Nordisk A/S

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-11
Primary Completion
2006-09-05
Completion
2006-09-05

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01492153 on ClinicalTrials.gov